Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial-Reference-Cited by-同舟云学术

Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial

Published:2021-03 Issue:3 Volume:22 Page:351-360
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Xu Binghe,Yan Min,Ma Fei,Hu Xichun,Feng Jifeng,Ouyang Quchang,Tong Zhongsheng,Li Huiping,Zhang Qingyuan,Sun Tao,Wang Xian,Yin Yongmei,Cheng Ying,Li Wei,Gu Yuanting,Chen Qianjun,Liu Jinping,Cheng Jing,Geng Cuizhi,Qin Shukui,Wang Shusen,Lu Jinsong,Shen Kunwei,Liu Qiang,Wang Xiaojia,Wang Hong,Luo Ting,Yang Jin,Wu Yudong,Yu Zhiyong,Zhu Xiaoyu,Chen Chunxia,Zou Jianjun

Publisher

Elsevier BV

Subject

Oncology

Reference29 articles.

1. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer;Slamon;Science,1989

2. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer;Baselga;N Engl J Med,2012

3. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study;Swain;Lancet Oncol,2013

4. Trastuzumab emtansine for HER2-positive advanced breast cancer;Verma;N Engl J Med,2012

5. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial;Diéras;Lancet Oncol,2017

Cited by 252 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeted gene panel sequencing of liquid and tissue biopsies reveals actionable genomic alterations in Ghanaian metastatic breast cancer cases;Translational Oncology;2024-11

2. Unraveling the future: Innovative design strategies and emerging challenges in HER2-targeted tyrosine kinase inhibitors for cancer therapy;European Journal of Medicinal Chemistry;2024-10

3. Efficacy and safety of pyrotinib-based regimens in HER2 positive metastatic breast cancer: A retrospective real-world data study;Neoplasia;2024-10

4. Questionnaire survey and analysis of drug clinical research implementation capabilities of breast cancer treatment departments in Chinese hospitals;The Breast;2024-10

5. First-in-human study of DP303c, a HER2-targeted antibody-drug conjugate in patients with HER2 positive solid tumors;npj Precision Oncology;2024-09-12